Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Naratuximab + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Naratuximab||IMGN 529|Debio 156|IMGN529||CD37 Antibody 6||Naratuximab (IMGN529) is an antibody-drug conjugate consisting of a humanized anti-CD37 monoclonal antibody linked to the anti-mitotic agent, maytansinoid DM1, thereby inducing cell death of B-cells expressing CD37 (PMID: 29453628).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 10||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02564744||Phase II||Naratuximab + Rituximab||Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL||Active, not recruiting|